We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
-12.22%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$569M
AUM Growth
-$103M
Cap. Flow
+$59.4M
Cap. Flow %
10.45%
Top 10 Hldgs %
78.53%
Holding
22
New
3
Increased
1
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$65.9M
2
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$15.8M
3
CDTX
Cidara Therapeutics
CDTX
+$14.6M
4
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$26.2K

Top Sells

Rank Stock Value
1
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$21.5M
2
CMRX
Chimerix, Inc.
CMRX
+$14.8M
3
ROKA
Sorrento Tech, Inc. Common Stock
ROKA
+$601K

Sector Composition

Rank Sector Weight
1 Healthcare 69.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLTQ
1
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$83.4M 14.66%
2,603,528
+790
+0% +$26.2K
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
$71.4M 12.55%
+2,820,000
New +$65.9M
CEMP
3
DELISTED
Cempra, Inc.
CEMP
$61.1M 10.73%
2,193,060
– –
LOXO
4
DELISTED
Loxo Oncology, Inc
LOXO
$60.4M 10.61%
3,452,493
– –
ESPR
5
DELISTED
Esperion Therapeutics
ESPR
$38.6M 6.79%
1,637,125
– –
ADMA icon
6
ADMA Biologics
ADMA
$1.99B
$30.2M 5.3%
3,608,171
– –
CMRX
7
DELISTED
Chimerix, Inc.
CMRX
$27.6M 4.85%
722,943
-300,000
-29% -$14.8M
ARAV
8
DELISTED
Aravive, Inc. Common Stock
ARAV
$26.3M 4.62%
379,928
– –
DERM
9
DELISTED
Dermira, Inc.
DERM
$25.7M 4.52%
1,102,046
– –
TTOO
10
DELISTED
T2 Biosystems, Inc
TTOO
$22.1M 3.89%
505
– –
AGRX
11
DELISTED
Agile Therapeutics
AGRX
$20.1M 3.54%
1,492
– –
ASXC
12
DELISTED
Asensus Surgical, Inc.
ASXC
$18.8M 3.31%
641,217
– –
CTLT
13
DELISTED
CATALENT, INC.
CTLT
$17.4M 3.06%
715,673
– –
CYNA
14
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$15.8M 2.77%
+975,191
New +$15.8M
PRTK
15
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$13M 2.28%
682,680
– –
CDTX
16
DELISTED
Cidara Therapeutics
CDTX
$13M 2.28%
+50,973
New +$14.6M
XENT
17
DELISTED
Intersect ENT, Inc
XENT
$8.19M 1.44%
350,000
– –
PTX
18
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$6.35M 1.12%
201,000
– –
EVAR
19
DELISTED
Lombard Medical, Inc.
EVAR
$3.16M 0.56%
886,363
– –
SRNE
20
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$2.97M 0.52%
353,855
-1,350,000
-79% -$21.5M
ROKA
21
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$1.58M 0.28%
81,189
-21,780
-21% -$601K

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q3 2015 Portfolio in Review

As of Q3 2015, Aisling Capital held 22 positions worth $569M, down 15% from $672M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Aisling Capital deployed $59.4M of net new capital in Q3 2015, opening 3 new positions and adding to 1 existing holding. Its largest new stake was Aimmune Therapeutics: 2,820,000 shares worth $71.4M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 80% a quarter earlier.

On the sell side, the largest reduction was Sorrento Therapeutics, Inc., an estimated $21.5M trimmed.

  • Aisling Capital's largest Q3 2015 buy was Aimmune Therapeutics: 2,820,000 shares worth $71.4M.
  • Aisling Capital added most to ZELTIQ Aesthetics, Inc. in Q3 2015, an estimated $26.2K increase.
  • Aisling Capital's biggest Q3 2015 reduction was Sorrento Therapeutics, Inc., cutting an estimated $21.5M.
  • Aisling Capital's ten largest holdings make up 79% of its $569M portfolio in Q3 2015.
  • Aisling Capital opened 3 new positions and closed 0 in Q3 2015.
  • Aisling Capital's portfolio value fell 15% quarter-over-quarter to $569M.

Based on Aisling Capital's 13F filing for Q3 2015, filed 13 Nov 2015.